Alprolix Approval History
Alprolix (coagulation factor IX (recombinant)) is a clotting factor IX therapy indicated to prevent bleeding in patients with hemophilia B.
Development History and FDA Approval Process for Alprolix
|Mar 28, 2014||FDA Approves Alprolix (recombinant coagulation factor IX) for patients with Hemophilia B|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.